Early Markers in Parkinson’s and Alzheimer’s Diseases

315 Pages·1990·10.82 MB·English

by  R. Levi Montalcini (auth.)

NewVistas
in Drug
Research
Vol. 1
P. Dostert, P. Riederer,
M. Strolin Benedetti, and R. Roncucci (eds.)
Early Markers in
Parkinson's and
Alzheimer's Diseases
Springer-Verlag Wien New York
Dr. Philippe Dostert
Farmitalia Carlo Erba, Milan, Italy
Prof. Dr. Peter Riederer
Department of Psychiatry, University of Wiirzburg, Federal Republic of Germany
Dr. Margherita Strolin Benedetti
Farmitalia Carlo Erba, Milan, Italy
Dr. Romeo Roncucci
Farmitalia Carlo Erba, Milan, Italy
This work ist subject to copyright.
All rights are reserved, whether the whole or part of the material is concerned, specifically those
of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying
machines or similar means, and storage in data banks.
© 1990 by Springer-Verlag/Wien
Softcover reprint of the hardcover 1st edition 1990
Printed on acid-free paper
Product Liability: The publisher can give no guarantee for information about drug dosage and
application thereof contained in this book. In every individual case the respective user must
check its accuracy by consulting other pharmaceutical literature. The use of registered names,
trademarks, etc. in this publication does not imply, even in the absence of a specific statement,
that such names are exempt from the relevant protective laws and regulations and therefore
free for general use.
With 38 Figures (1 in color)
Library of Congress Cataloging-in-Publication Data. Early markers in Parkinson's and Alzhei
mer's diseases/Po Dostert (et al.) (eds.) p., cm. (New vistas in drug research; vol. 1.) Based
on a conference which was organized by Erbamont and Carlo Erba Foundation. Includes index.
ISBN-13:978-3-7091-9100-2 1. Parkinsonism-Diagnosis-Congresses. 2. Alz-
heimer's disease-Diagnosis-Congresses. 3. Biochemical markers-Congresses. 1. Dostert, P.
II. Erbamont Inc. III. Fondazione Carlo Erba. IV. Series. [DNLM: 1. Alzheimer's Disease-
diagnosis-congresses. 2. Alzheimer's Disease--physiopathology-congresses. 3. Biological
Markers--congresses. 4. Parkinson's Disease--diagnosis-congresses. 5. Parkinson's Disease--
physiopathology-congresses. WL 359 E12] RC382.E38 1990. 616.8'31075-dc20. 90-10419
ISSN 0938-9245
ISBN-13:978-3-7091-9100-2 e-JSBN-13:978-3-7091-9098-2
DOl: 10.1007/978-3-7091-9098-2
Welcome address
I am really honored to open this first meeting of "New Vistas in Drug
Research-Dialogues for the future" and to heartily welcome all the scientists,
coming from 14 countries, who have accepted to offer here their contribution
to exchange different experiences and to create new grounds for further
scientific advances.
The fact that Erbamont, along with the Carlo Erba Foundation, has
organized this meeting is only a detail. We believe, as all the other phar
maceutical companies based on a strong research and development, that we
need to be more and more open to the scientific world, whose frontiers are
getting broader day by day at an increasing speed. We have to run fast in
this world and moments like these can give us the intellectual energy to run
even faster.
I am sure you will have a very productive and stimulating meeting.
Thank you again for coming.
P. Morrione
Erbamont, President and Chief Executive Officer
New Vistas today and tomorrow
Dr. Montalcini, Dr. Guillemin, Dear Colleagues, the title of this series
of meetings, "New Vistas in Drug Research" reflects the magic moment the
pharmaceutical sciences are presently living, due to the tremendous progress
of basic research, and of molecular biology in particular. Thanks to this
progress, we are now sitting on the top of a hill from which we can look at
the huge horizon with the various disciplines growing fast and cross-reacting
with each other. Basic research is no longer isolated in an ivory tower but
it's becoming the foundation on top of which new intelligent drugs can be
built up.
Based on the above, aim of these meetings is to stimulate dialog and
constructive interaction between scientists with different background and of
different affiliations. We are confident of the results of this cross-fertilization
which could lead to new approaches for the topics that will be discussed in
our New Vistas meetings. Today we are inaugurating the first of these
meetings, whose title is "Early Markers in Parkinson's and Alzheimer's Dis
eases". Already nowadays, but even more in the future, neurodegenerative
disorders will constitute a major health problem, especially in developed
countries. Despite advances in research, the management of these diseases is
still hampered by the lack of a full understanding of their etiology and physio
pathology. It is, however, our belief that with the increased knowledge of
the real mechanisms involved in these pathological conditions, it seems now
possible, within a reasonable period of time, to find more dedicated drug
treatments for these terrible diseases. Parallely with this goal, it appears now
possible to identify also reliable biological markers which could predict the
onset of the disease at very early stages, possibly before lesions appear, giving
doctors efficacious tools to check and monitor the presence of the disease or
its evolution in association with new treatments.
I sincerely hope that the discussions which will take place during this
two-day meeting will contribute to the progress in this direction. Before
leaving the floor to Dr. Montalcini, I wish to express my sincere thanks to
all of you for having accepted to participate in this first New Vistas meeting.
Thank you.
R. Roncucci
Erbamont, Research and Development, Vice President
Acknowledgments
The Editors are grateful to Patrizia Di Rosa for her dedicated assistance
in the preparation of this volume.
The Organizing Committee is deeply indebted to Patrizia Di Rosa, Gio
vanna Garattini, Nadia La Spada, Luisa Stea and Rosanna Romaniello for
their skilful contribution towards the success of the meeting.
Contents
Contributors . . XIII
List of abbreviations . XIX
Levi Montalcini, R.: Introduction
EarlY markers in Parkinson's disease
Przuntek, H.: Early markers in Parkinson's disease . 5
Agnoli, A., Stocchi, F., Carta, A.: Differential diagnosis of Parkinson's disease 13
Poewe, W.: The premorbid personality of patients with Parkinson's disease 23
Carvey, P. M., Klawans, H. L., Kao, L. C., Dahlstrom, A., McRae, A.: An
antibody in the CSF of Parkinson's disease patients: summary of data and
potential role as a diagnostic marker 31
Kraus, P. H., Klotz, P., Steinberg, R., Przuntek, H.: Contribution of motor
performance tests to the early diagnosis of Parkinson's disease . 41
Liicking, C. H., Hufschmidt, A., Deuschl, G.: Electrophysiological methods
in the early diagnosis of Parkinson's disease 49
Leenders, K. L.: Characterization of Parkinson's disease using positron emission
tomography 59
Nagatsu, T., Mogi, M., Harada, M., Kojima, K.: Dopamine beta-hydroxylase
and beta 2-microglobulin in cerebrospinal fluid: early markers in Parkinson's
disease? . 71
Kienzl, E., Eichinger, K., Jellinger, K., Kuhn, W., Fuchs, G., Danielczyk,
W., Wesemann, W., Riederer, P.: Urinary dopamine sulfate conjugates in
Parkinson's disease . 79
Dostert, P., Strolin Benedetti, M., Dordain, G.: Salsolinol and the early de-
tection of Parkinson's disease . 93
Olanow, C. W., Alberts, M., Djang, W., Stajich, J.: MR imaging of putamenal
iron predicts response to dopaminergic therapy in parkinsonian patients 99
Youdim, M. B. H., Ben-Shachar, D.: The neurotoxic component in Parkinson's
disease may involve iron-melanin interaction and lipid peroxidation in the
substantia nigra . 111
Round table on Parkinson's disease . 123
EarlY markers in Alzheimer's disease
Murphy, D. L., Sunderland, T.: The need for early markers in Alzheimer's
disease 137
Amaducci, L., Lippi, A.: Descriptive and analytic epidemiology of Alzheimer's
disease 147
XII Contents
Gottfries, C. G.: Differential diagnosis of early Alzheimer's disease 155
Delabar, J. M., Blouin, J. L., Rahmani, Z., Creau-Goldberg, N., Chettouh,
Z., Nicole, A., Bruel, A., de Blois, M. C., Sinet, P. M.: Down syndrome:
a model for the study of Alzheimer's disease and aging 165
Heiss, W.-D., Szelies, B., Adams, R., Kessler, ]., Pawlik, G., Herholz, K.:
PET scanning for the detection of Alzheimer's disease. . 181
Dierks, T., Maurer, K.: Reference-free evaluation of auditory evoked poten-
tials-P300 in aging and dementia. .... 197
McBean, G.]., Horner, E. B., Couee, I., Phillips, J. P., O'Brien, M., Lee,
T. C., Tipton, K. F.: Enzymes and glial cells in brain damage and neuro-
degenerative diseases . 209
Riederer, P., Sofie, E., Moll, G., Freyberger, A., Wiehart, I., Gsell, W.,
Jellinger, K., Hebenstreit, G., Youdim, M. B. H.: Senile dementia of
Alzheimer's type and Parkinson's disease: neurochemical overlaps and specific
differences . . 221
Hoyer, S.: Changes in brain energy metabolism and the early detection of
Alzheimer's disease. . 233
Nordberg, A.: Choline metabolism in Alzheimer's disease: hints as to possible
markers . . . . . . . . . .. .... 245
McRae, A., Blennow, K., Wallin, A., Fredman, P., Gottfries, C. G., Dahl
strom, A.: The presence of anti brain antibodies in the CSF of some Alzheimer
disease patients: correlation with CSF parameters . 257
Oreland, L., Hiraga, Y., Jossan, S. S., Regland, B., Gottfries, C. G.: Increased
monoamine oxidase activity and vitamin B-12 deficiency in dementia disorders 267
Round table on Alzheimer's disease 287
Guillemin, R.: Closing remarks 299
Subject index 303
Contributors *
Adams, R. (181) Universitatsklinik fur Neurologie, Joseph-Stelzmann-Strasse 9,
D-W-5000 Koln 41 (Lindenthal), Federal Republic of Germany.
Agnoli, A. (13) I Clinic of Neurology, Department of Neurosciences, University "La
Sapienza", Viale dell'Universid 30, 1-00185 Rome, Italy.
Alberts, M. (99) Duke University, Department of Medicine, Service of Neurology,
Durham, NC, U.S.A.
Amaducci, L. (147, 287) Istituto delle Malattie Nervose e Mentali dell'Universid di
Firenze, Viale Morgagni 85, 1-50134 Florence, Italy.
Ben-Shachar, D. (111) Rappaport Research Institute, Department of Pharmacology,
Faculty of Medicine, Technion, Haifa, Israel.
Blennow, K. (257) Department of Psychiatry and Neurochemistry, St. Jorgens Hos
pital, University of Goteborg, S-42203 Hisings Backa, Sweden.
de Blois, M. C (165) H6pital Necker, Service de Cytogenetique, 149 rue de Sevres,
F-75743 Paris, France.
Blouin, J. L. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de
Sevres, F-75743 Paris, France.
Bruel, A. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de
Sevres, F-75743 Paris, France.
Brun, A. (287) Department of Pathology, Division of Neuropathology, University
Hospital, S-221 85 Lund, Sweden.
CaIne, D. B. (123) U.B.C Health Sciences Centre Hospital, Faculty of Medicine, 2211
Wesbrook Mall, Vancouver B.C, Canada V6TIW5.
Caraceni, T. (123) Istituto Neurologico C Besta, Via Celoria 11, 1-20133 Milan, Italy.
Carta, A. (13) I Clinic of Neurology, Department of Neurosciences, University "La
Sapienza", Viale dell'Universita 30, 1-00185 Rome, Italy.
Carvey, P. M. (31) Department of Neurological Sciences, Rush-Presbyterian St. Lukes
Medical Center, 1753 West Harrison St., Chicago, IL 60616, U.S.A.
Chettouh, Z. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de
Sevres, F-75743 Paris, France.
Couee, 1. (209) Department of Biochemistry, Trinity College, Dublin 2, Ireland.
Creau-Goldberg, N. (165) H6pital Necker, INSERM U173, 149 rue de Sevres,
F-75743 Paris, France.
Dahlstrom, A. (31, 257) University of Goteborg, Institute of Neurobiology, P.O.B.
33031, S-40033 Goteborg, Sweden.
Danielczyk, W. (79) LBI fUr Altersforschung, Neurologische Abteilung des Pflege
heimes Lainz, Versorgungsheimplatz 1, A-1130 Wien, Austria.
* Numbers in parentheses indicate the pages on which the authors' contributions begin.